Professor of Medicine, Mayo Medical School
Oncology
Dr. Charles L. Loprinzi, MD
|
|
Give Review
Charles L. Loprinzi works in the field of Oncology. He attended Oregon Health & Science University School of Medicine. He has 3 awards "America's Top Doctors", "America's Top Doctors for Cancer" and "Fellow (FASCO)". Charles Loprinzi is a published MD. He has 98 publications published. The most current publication "National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons." He accepts all Medicare patients.
Publications
- Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes.
- MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.
- National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons.
- Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast Cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
- Can pregabalin prevent paclitaxel-associated neuropathy?-An ACCRU pilot trial.
- Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
- Antidepressants decrease hot flashes and improve life quality.
- Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group Cancer clinical trials N02C1 and N03CC (Alliance).
- Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung Cancer patients.
- Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With ColoRectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicente...
- ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer.
- Therapeutic strategies for Cancer treatment related peripheral neuropathies.
- Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult Cancers: american society of clinical oncology clinical practice guidelin...
- North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.
- Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.
- Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emet...
- Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with coloRectal, breast, lung, and prostate cancer.
- An Analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.
- Management options for established chemotherapy-induced peripheral neuropathy.
- Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
- North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 rand...
- Supportive Cryotherapy: A Review From Head to Toe.
- Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of ColoRectal Cancer: American Society of Clinical Oncology Clinical Practice Gu...
- Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial Analysis, N09C1.
- Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons.
- Antiemetic prescribing practices using a computerized physician order entry System.
- Breast Cancer survivorship issues.
- Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2.
- End-of-life care in a population-based cohort of Cancer patients: clinical trial participation versus standard of care.
- The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast Cancer, N00C9.
- Randomized phase II trial of sulindac for lung Cancer chemoprevention.
- Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.
- Extinguishing hot flash therapy.
- Hot flashes and antidepressant agents: uneasy bedfellows.
- Hot flashes: the ongoing search for effective interventions.
- Palliative communications: addressing chemotherapy in patients with advanced Cancer.
- Further data supporting that paclitaxel-associated Acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group tr...
- Nonestrogenic management of hot flashes.
- Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21-Gene Recurrence Score.
- Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-Analysis (N0993).
- A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7.
- Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment ...
- Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia.
- Antiemetics for Chemotherapy-Induced Nausea and Vomiting Occurring Despite Prophylactic Antiemetic Therapy.
- A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA.
- The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-...
- Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1.
- Mometasone furoate effect on Acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Ca...
- Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon Cancer: NCCTG N04C7.
- The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for Cancer: a phase III randomized, placebo-controlled, double-...
- Phase III, randomized study of the effects of parenteral iron, Oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients wi...
- Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast Cancer survivors.
- The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial.
- Nonhormonal management of hot flashes for women on risk reduction therapy.
- Compassionate honesty.
- Comparison of Provider-Assessed and Patient-Reported Outcome Measures of Acute Skin Toxicity During a Phase III Trial of Mometasone Cream Versus Placebo During Breast ...
- Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treat...
- Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for Cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05...
- Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.
- Coprescription of tamoxifen and medications that inhibit CYP2D6.
- Pilot evaluation of a stellate ganglion block for the treatment of hot flashes.
- Gabapentin for the management of hot flashes in prostate Cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB.
- Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1.
- Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States.
- Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Gr...
- Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration.
- On hot flash mechanism, measurement, and treatment.
- Gadgets for measuring hot flashes: have they become the gold standard?
- Newer antidepressants and gabapentin for hot flashes: an individual patient pooled Analysis.
- A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).
- Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary ...
- High detection rates of coloRectal neoplasia by stool DNA testing with a novel digital melt curve assay.
- Newer antidepressants for hot flashes--should their efficacy still be up for debate?
- Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced Cancer.
- Stool DNA and occult blood testing for screen detection of coloRectal neoplasia.
- Symptom management in premenopausal patients with breast Cancer.
- Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment G...
- Minocycline for preventing EGFR inhibitor-induced rash.
- Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience.
- Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3.
- Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.
- Physical activity in patients with advanced-stage Cancer actively receiving chemotherapy.
- The Paclitaxel Acute pain syndrome: sensitization of nociceptors as the putative mechanism.
- A placebo-controlled double blind trial of etanercept for the Cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
- Phase II Evaluation of Desipramine for the Treatment of Hot Flashes.
- Randomized controlled trial to evaluate transdermal testosterone in female Cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.
- Tamoxifen-associated hot flashes in women.
- Does zinc sulfate prevent therapy-induced taste alterations in head and neck Cancer patients? Results of phase III double-blind, placebo-controlled trial from the Nort...
- Symptom control trials: a 20-year experience.
- A critical review of complementary therapies for Cancer-related fatigue.
- Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.
- Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressa...
- Whose opinion counts?
- Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
- Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
- Newer antidepressants inhibit hot flashes.
Schools
Oregon Health And Science University School Of Medicine
Maricopa Co Hospital
University Of Wisconsin Madison
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Fellow (FASCO)
Education
-
University of Wisconsin -
Maricopa Medical Center -
Oregon Health & Science University School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1194704676 | |
| NPPES Provider LastName | LOPRINZI | |
| NPPES Provider FirstName | CHARLES | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 221.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1194704676 |
| Last Name Of The Provider | LOPRINZI |
| First Name Of The Provider | CHARLES |
| View All |
Similar Doctors
|
|
Dr. Charles Erlichman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian A. Costello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randolph S. Marks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joleen M. Hubbard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph Rubin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arif H. Kamal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cynthia J. Wetmore, MD |
|
|
Dr. Frank A. Sinicrope, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evanthia Galanis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minetta Liu, MD
This Doctor is OpenDoctor Recommended.
|